pharmafileNovember 20, 2018
Tag: Sequiris , Laura O'Brien , British
The Liverpool-based vaccine-maker Sequiris is investing £40 million into the expansion of its operations in the Speke area of Liverpool.
The multi-million pound investment is set to create 100 new jobs while allowing vaccines to be created more quickly in preparation for outbreaks of the flu. While vaccines are currently shipped to Italy for packaging, the expansion will now allow the process of packing the vaccines into syringes and capsules to be done in the UK.
The company, which is as of now the second biggest influenza vaccine company in the world, provides around half of the vaccines used in the UK. The project which is expected to be complete in 2019 will increase the safety of the government contracted vaccine makers products.
The investment will also increase the speed with which vaccines reach the market in the UK.
Dr Laura O'Brien, vice president of operations and site head at Liverpool, commented: "This investment means we can complete production of more pandemic vaccine much more rapidly, saving vital days in getting vaccines out to protect the British population as well as to other countries around the world."
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: